Tag: Serotonin-norepinephrine reuptake inhibitor

  • Milnacipran

    Serotonin-norepinephrine reuptake inhibitor

    An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

    Abstract

    Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Venlafaxine

    Serotonin-norepinephrine reuptake inhibitor

    A bicyclic SNRI with dose-dependent transporter selectivity; the prototype dual-action antidepressant.

    Abstract

    Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CAS 93413-69-5; molecular formula C17H27NO2; molecular weight 277.40) is a bicyclic phenethylamine SNRI developed at Wyeth and approved by the FDA in 1993 under the trade name Effexor. The active metabolite O-desmethylvenlafaxine (desvenlafaxine, marketed separately as Pristiq) carries comparable transporter activity and contributes substantially to the steady-state effect. Plasma half-life of the parent compound is approximately 5 hours; the metabolite half-life is approximately 11 hours. Metabolism is via CYP2D6 (primary) and CYP3A4 (secondary). The compound exhibits a pronounced discontinuation syndrome, attributed to the short half-life and combined serotonergic-noradrenergic withdrawal. Used as the reference SNRI in mechanism studies and as a positive control in dual-action antidepressant pharmacology research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Duloxetine

    Serotonin-norepinephrine reuptake inhibitor

    A balanced-affinity SNRI distinguished by approval for chronic pain and diabetic peripheral neuropathy in addition to depression.

    Abstract

    Duloxetine ((S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; CAS 116539-59-4; molecular formula C18H19NOS; molecular weight 297.41) is a balanced-affinity SNRI developed at Eli Lilly and approved by the FDA in 2004 under the trade name Cymbalta. SERT (Ki approximately 0.8 nM) and NET (Ki approximately 7.5 nM) affinities are both nanomolar, with a SERT/NET ratio of roughly 10, more balanced than venlafaxine (ratio approximately 30). The compound exhibits weak DAT inhibition (Ki approximately 240 nM) of marginal clinical relevance. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2 (primary) and CYP2D6 (secondary). The compound is itself a moderate CYP2D6 inhibitor, producing relevant interactions with TCAs, antipsychotics, and tamoxifen. Approved indications include major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain. The pain indications reflect the noradrenergic component’s role in descending pain modulation. Used as the canonical balanced SNRI in mechanism studies and as a reference compound for descending pain modulation research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.